載入中
NASDAQHealthcareBiotechnology
最新資料
US$1.90
−US$0.01 · -0.52%
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
收盤時
US$1.90
−US$0.01 · -0.52%
盤後
US$1.91
+US$0.01 · +0.53%
10月12日 下午4:29 ET
盤中時間採用ET。市場資料可能有所延遲。
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
日內區間
目前US$1.90
52週區間
目前US$1.90
盤中時間採用ET。市場資料可能有所延遲。
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
日內區間
目前US$1.90
52週區間
目前US$1.90
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 135.6萬 USD | 100.6萬 USD | 53.6萬 USD | — | — |
| 毛利 | −135.6萬 USD | −100.6萬 USD | −53.6萬 USD | — | — |
| 研究與開發 | 5999萬 USD | 6399.2萬 USD | 4548.8萬 USD | 2394.9萬 USD | 1371.8萬 USD |
| 銷售、一般及管理費用 | 2412.4萬 USD | 2520.7萬 USD | 2121.3萬 USD | 870.8萬 USD | 246.6萬 USD |
| 營業費用 | 8275.8萬 USD | 8819.3萬 USD | 6670.1萬 USD | 3265.7萬 USD | 1618.4萬 USD |
| 利息收入 | 647.9萬 USD | 920.1萬 USD | 703.7萬 USD | — | — |
| 折舊和攤銷 | 135.6萬 USD | 100.6萬 USD | 53.6萬 USD | 36.4萬 USD | 3.7萬 USD |
| 營業利益 | −8411.4萬 USD | −8919.9萬 USD | −6723.7萬 USD | −3265.7萬 USD | −1618.4萬 USD |
| 淨利 | −7790.5萬 USD | −8055.6萬 USD | −6038.8萬 USD | −3116.7萬 USD | −1624.3萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$21.83
上漲空間 1048.95%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI114.02萬0.00%2.3兆 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF81.42萬0.00%954億 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC11.85萬0.01%13.17億 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM11萬0.09%1.17億 USD0.73%US$15.86-0.50%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.32萬0.00%61.81億 USD0.26%US$68.32+0.06%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMU.S. Vector Equity Portfolio ETF Class SharesDXUVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
